Logo image of GKOS

GLAUKOS CORP (GKOS) Stock Price, Quote, News and Overview

NYSE:GKOS - New York Stock Exchange, Inc. - US3773221029 - Common Stock - Currency: USD

97.6  0 (0%)

After market: 97.6 0 (0%)

GKOS Quote, Performance and Key Statistics

GLAUKOS CORP

NYSE:GKOS (6/13/2025, 8:04:45 PM)

After market: 97.6 0 (0%)

97.6

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High163.71
52 Week Low77.1
Market Cap5.58B
Shares57.14M
Float55.27M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-29 2025-07-29/amc
IPO06-25 2015-06-25


GKOS short term performance overview.The bars show the price performance of GKOS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20

GKOS long term performance overview.The bars show the price performance of GKOS in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60 80 100

The current stock price of GKOS is 97.6 USD. In the past month the price increased by 6.53%. In the past year, price decreased by -13.32%.

GLAUKOS CORP / GKOS Daily stock chart

GKOS Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 28.37 235.96B
ISRG INTUITIVE SURGICAL INC 67.04 183.58B
BSX BOSTON SCIENTIFIC CORP 36.94 147.56B
SYK STRYKER CORP 30.11 144.19B
MDT MEDTRONIC PLC 15.87 111.93B
BDX BECTON DICKINSON AND CO 12.22 49.36B
EW EDWARDS LIFESCIENCES CORP 28.9 44.08B
IDXX IDEXX LABORATORIES INC 45.85 42.36B
RMD RESMED INC 27.46 36.56B
GEHC GE HEALTHCARE TECHNOLOGY 15.71 33.08B
DXCM DEXCOM INC 49.69 32.15B
STE STERIS PLC 25.84 23.71B

About GKOS

Company Profile

GKOS logo image Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 995 full-time employees. The company went IPO on 2015-06-25. The firm is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Company Info

GLAUKOS CORP

1 Glaukos Way

Aliso Viejo CALIFORNIA 92672 US

CEO: Thomas W. Burns

Employees: 995

GKOS Company Website

GKOS Investor Relations

Phone: 19493679600

GLAUKOS CORP / GKOS FAQ

What is the stock price of GLAUKOS CORP today?

The current stock price of GKOS is 97.6 USD.


What is the ticker symbol for GLAUKOS CORP stock?

The exchange symbol of GLAUKOS CORP is GKOS and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is GKOS stock listed?

GKOS stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for GLAUKOS CORP stock?

21 analysts have analysed GKOS and the average price target is 126.14 USD. This implies a price increase of 29.24% is expected in the next year compared to the current price of 97.6. Check the GLAUKOS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GLAUKOS CORP worth?

GLAUKOS CORP (GKOS) has a market capitalization of 5.58B USD. This makes GKOS a Mid Cap stock.


How many employees does GLAUKOS CORP have?

GLAUKOS CORP (GKOS) currently has 995 employees.


What are the support and resistance levels for GLAUKOS CORP (GKOS) stock?

GLAUKOS CORP (GKOS) has a support level at 93.22 and a resistance level at 97.61. Check the full technical report for a detailed analysis of GKOS support and resistance levels.


Is GLAUKOS CORP (GKOS) expected to grow?

The Revenue of GLAUKOS CORP (GKOS) is expected to grow by 26.94% in the next year. Check the estimates tab for more information on the GKOS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GLAUKOS CORP (GKOS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GLAUKOS CORP (GKOS) stock pay dividends?

GKOS does not pay a dividend.


When does GLAUKOS CORP (GKOS) report earnings?

GLAUKOS CORP (GKOS) will report earnings on 2025-07-29, after the market close.


What is the Price/Earnings (PE) ratio of GLAUKOS CORP (GKOS)?

GLAUKOS CORP (GKOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.42).


What is the Short Interest ratio of GLAUKOS CORP (GKOS) stock?

The outstanding short interest for GLAUKOS CORP (GKOS) is 6.07% of its float. Check the ownership tab for more information on the GKOS short interest.


GKOS Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to GKOS. When comparing the yearly performance of all stocks, GKOS is a bad performer in the overall market: 76.52% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

GKOS Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to GKOS. GKOS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GKOS Financial Highlights

Over the last trailing twelve months GKOS reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS increased by 40.34% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -12.8%
ROE -16.19%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%68.57%
Sales Q2Q%24.58%
EPS 1Y (TTM)40.34%
Revenue 1Y (TTM)23.92%

GKOS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to GKOS. The Buy consensus is the average rating of analysts ratings from 21 analysts.

For the next year, analysts expect an EPS growth of 54.21% and a revenue growth 26.94% for GKOS


Ownership
Inst Owners101.3%
Ins Owners3.28%
Short Float %6.07%
Short Ratio3.32
Analysts
Analysts82.86
Price Target126.14 (29.24%)
EPS Next Y54.21%
Revenue Next Year26.94%